E de Stanchina - Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol, Antitumor Assessment Core Facil, 1275 York Ave, New York, NY 10021 USA

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 22 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

228P SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGFβ signaling

Á. Quintanal-Villalonga, E. Costa, C. Wohlheiter, S. Tischfield, E. Redin, H. Sridhar, A. Funnel, J.T. Poirier, Y. Hao, D. Kinyua, B. de Mello, J.E. Lazar,

ESMO Open (2024)

引用0浏览0引用

2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate

Á. Quintanal-Villalonga, S. Zaidi, W.R. Karthaus, Y.A. Zhan, M. Shafer, J. Qiu,E. de Stanchina, M.C. Haffner,C.L. Sawyers,C.M. Rudin

Annals of Oncology (2023): S1150-S1150

引用0浏览0引用

1MO Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation

Á. Quintanal-Villalonga, H. Taniguchi,Y.A. Zhan,M.M. Hasan,S.S. Chavan,F. Uddin, V. Allaj,P. Manoj,N. Shah,M. Ciampricotti, U. Bhanot, J. Egger,

Annals of Oncology（2021）

引用0浏览0引用

CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer

A. Quintanal-Villalonga,H. Taniguchi,Y. Hao,A. Chow,Y. Zhan,S. Chavan,F. Uddin, V. Allaj,P. Manoj,N. Shah,J. Chan,M. Offin,

JOURNAL OF THORACIC ONCOLOGY（2021）

引用0浏览0引用

LSD1 inhibition restores MHC class I expression and augments the anti-tumor response of immune checkpoint blockade in small cell lung cancer

T. Sen, M. N. Nguyen,H. Taniguchi,A. Chow,E. De Stanchina,C. M. Rudin

Annals of Oncology（2021）

引用0浏览0引用

2MO XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer

Á. Quintanal-Villalonga, H. Taniguchi, Y. Hao,A. Chow,Y.A. Zhan,F. Uddin, V. Allaj,P. Manoj,N. Shah,J.M. Chan, M. Offin,M. Ciampricotti,

Annals of Oncology（2021）

引用0浏览0引用

MA16.03 CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer

Álvaro Quintanal-Villalonga,Hirokazu Taniguchi,Yuan Hao,Andrew Chow,Yingqian Zhan,Shweta S. Chavan,Fathema Uddin,Viola Allaj,P. Manoj,Nisargbhai S. Shah,Joseph M. Chan,Michael Offin,

Journal of Thoracic Oncology（2021）

引用0浏览0引用

P1.12-15 PET Imaging of [18F]PARP Inhibitor as a Pharmacodynamic Biomarker of Talazoparib in Small Cell Lung Cancer PDXs

B. Lok,J. Laird,B. Carney,S. Kossatz,E. De Stanchina,T. Reiner,J. Poirier,C. Rudin

JOURNAL OF THORACIC ONCOLOGY（2019）

引用0浏览0引用

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

P. Mondello,S. Tadros,M. Teater,L. Fontan,A. Chang,N. Jain,S. Singh,M. C. J. Ma,H. Yang,E. Toska,S. Alig,M. Durant,

bioRxiv（2019）

引用84浏览0引用

Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics

C. H. Hulton,E. A. Costa,N. S. Shah,A. Quintanal-Villalonga,G. Heller,E. de Stanchina,C. M. Rudin,J. T. Poirier

bioRxiv（2019）

引用19浏览0WOSNATURE引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn